Atlas Trials

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Clinical trial NCT05696717 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05696717
Sponsor
Theravance Biopharma
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Symptomatic Neurogenic Orthostatic HypotensionMSA - Multiple System Atrophy
Start date
2023-06-27
Primary completion
2026-01-01
Enrollment
102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.